Publications by authors named "J Esteban-Villarrubia"
Background: Cabazitaxel and Lu-PSMA-617 have been shown to improve survival in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel and androgen receptor pathway inhibitors (ARPI). we aimed to evaluate the impact of sequencing cabazitaxel and Lu-PSMA-617 on survival outcomes in patients with mCRPC.
Patients And Methods: This is a retrospective, multicenter, cohort study which included patients with mCRPC who received sequential treatment with Lu-PSMA-617 and cabazitaxel between January 2015 and December 2023.
Cancer immunotherapies with antibodies blocking immune checkpoint molecules are clinically active across multiple cancer entities and have markedly improved cancer treatment. Yet, response rates are still limited, and tumour progression commonly occurs. Soluble and cell-bound factors in the tumour microenvironment negatively affect cancer immunity.
View Article and Find Full Text PDFArticle Synopsis
- KRAS mutations are common in non-small-cell lung cancer (NSCLC), making this a diverse group of cancers that respond differently to therapies compared to other types of cancer.
- Despite being considered "undruggable" for years, new direct KRAS inhibitors like sotorasib and adagrasib have gained FDA approval, revolutionizing treatment options for patients with previously treated KRAS-mutated NSCLC.
- While these inhibitors mark a major advancement, they are not curative and resistance mechanisms need to be understood, prompting ongoing research into new inhibitors and combination therapies, including those with immune checkpoint inhibitors.
Introduction: While surgical management of renal cell carcinoma (RCC) is curative for many patients, others may relapse and could benefit from adjuvant treatments. Immune checkpoint inhibitors (ICI) have been proposed as a potential adjuvant therapy for improving survival in these patients, but the benefit/risk ratio of ICI in the perioperative setting remains unclear.
Methods: A systematic review and a meta-analysis of phase III trials of perioperative ICI (anti PD1/PD-L1 alone or in combination with anti-CTLA4 agents) in RCC was conducted.